The Conversation (0)
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY.
2025 Stifel Healthcare Conference
Format: Fireside chat and one-on-one meetings
Date: Wednesday, November 12, 2025
Time: 4:40 pm ET
Webcast: Click here
Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at www.senseonics.com .
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
